3000 PEGASUS PARK DRIVE, DALLAS, TX
Market cap: $1.4B (12/18/2025)
Price: $5.49
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting
Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
News, Articles of Incorporation
Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Amended material disclosure
Q3
Q2
Q1
FY 2023
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report